[ ]
|
Rule 13d-1(b)
|
[ ]
|
Rule 13d-1(c)
|
[X]
|
Rule 13d-1(d)
|
CUSIP NO. 24823R105
|
|
1.
|
Names of Reporting Persons
|
2.
|
Check the Appropriate Box If a Member of a Group (See Instructions)
|
a.
|
[ ]
|
b.
|
[X]
|
3.
|
SEC Use Only
|
4.
|
Citizenship or Place of Organization
|
|
5.
|
Sole Voting Power
|
Number of
Shares
|
|
0
|
Beneficially
Owned By
Each
|
6.
|
Shared Voting Power
12,348,784 (1)
|
Reporting
Person
With
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
|
|
|
12,348,784 (1)
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
10.
|
Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11.
|
Percent of Class Represented By Amount in Row (9)
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Consists of 12,201,634 shares of Common Stock of Denali Therapeutics Inc. (the “Issuer”) held by AKDL, L.P. (“AKDL”) and 147,150 shares of Common Stock of the Issuer received by entities controlled by Douglas K.
Bratton in a pro rata in-kind distribution from Neuro Line Partners, L.P. As explained more fully in Item 2(a) herein, Mr. Bratton ultimately controls AKDL and may be deemed to have voting and investment power over all of the shares held by
AKDL.
|
(2)
|
Based on 119,918,496 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 5,
2020.
|
CUSIP NO. 24823R105
|
|
1.
|
Names of Reporting Persons
|
2.
|
Check the Appropriate Box If a Member of a Group (See Instructions)
|
a.
|
[ ]
|
b.
|
[X]
|
3.
|
SEC Use Only
|
4.
|
Citizenship or Place of Organization
|
|
5.
|
Sole Voting Power
|
Number of
Shares
|
|
0
|
Beneficially
Owned By
Each
|
6.
|
Shared Voting Power
12,201,634 (1)
|
Reporting
Person
With
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
|
|
|
12,201,634 (1)
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
10.
|
Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11.
|
Percent of Class Represented By Amount in Row (9)
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Consists of 12,201,634 shares of Common Stock of the Issuer held by AKDL. Crestline Investors, Inc. is the general partner of AKDL’s investment manager and general partner and may be deemed to beneficially own
these shares held by AKDL.
|
(2)
|
Based on 119,918,496 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020.
|
CUSIP NO. 24823R105
|
|
1.
|
Names of Reporting Persons
|
2.
|
Check the Appropriate Box If a Member of a Group (See Instructions)
|
a.
|
[ ]
|
b.
|
[X]
|
3.
|
SEC Use Only
|
4.
|
Citizenship or Place of Organization
|
|
5.
|
Sole Voting Power
|
Number of
Shares
|
|
0
|
Beneficially
Owned By
Each
|
6.
|
Shared Voting Power
12,201,634 (1)
|
Reporting
Person
With
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
|
|
|
12,201,634 (1)
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
10.
|
Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11.
|
Percent of Class Represented By Amount in Row (9)
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Consists of 12,201,634 shares of Common Stock of the Issuer held by AKDL. Crestline Management, L.P. is the investment manager of AKDL and may be deemed to beneficially own these shares held by AKDL.
|
(2)
|
Based on 119,918,496 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020.
|
CUSIP NO. 24823R105
|
|
1.
|
Names of Reporting Persons
|
2.
|
Check the Appropriate Box If a Member of a Group (See Instructions)
|
a.
|
[ ]
|
b.
|
[X]
|
3.
|
SEC Use Only
|
4.
|
Citizenship or Place of Organization
|
|
5.
|
Sole Voting Power
|
Number of
Shares
|
|
0
|
Beneficially
Owned By
Each
|
6.
|
Shared Voting Power
12,201,634 (1)
|
Reporting
Person
With
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
|
|
|
12,201,634 (1)
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
10.
|
Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11.
|
Percent of Class Represented By Amount in Row (9)
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Consists of 12,201,634 shares of Common Stock of the Issuer held by AKDL. Crestline SI (GP), L.P. is the general partner of AKDL and may be deemed to beneficially own these shares held by AKDL.
|
(2)
|
Based on 119,918,496 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020.
|
CUSIP NO. 24823R105
|
|
1.
|
Names of Reporting Persons
|
2.
|
Check the Appropriate Box If a Member of a Group (See Instructions)
|
a.
|
[ ]
|
b.
|
[X]
|
3.
|
SEC Use Only
|
4.
|
Citizenship or Place of Organization
|
|
5.
|
Sole Voting Power
|
Number of
Shares
|
|
0
|
Beneficially
Owned By
Each
|
6.
|
Shared Voting Power
12,201,634
|
Reporting
Person
With
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
|
|
|
12,201,634
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
10.
|
Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11.
|
Percent of Class Represented By Amount in Row (9)
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Based on 119,918,496 shares of Common Stock outstanding as of October 28, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020.
|
CUSIP NO. 24823R105
|
|
1.
|
Names of Reporting Persons
|
2.
|
Check the Appropriate Box If a Member of a Group (See Instructions)
|
a.
|
[ ]
|
b.
|
[X]
|
3.
|
SEC Use Only
|
4.
|
Citizenship or Place of Organization
|
|
5.
|
Sole Voting Power
|
Number of
Shares
|
|
0
|
Beneficially
Owned By
Each
|
6.
|
Shared Voting Power
0
|
Reporting
Person
With
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
|
|
|
0
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
10.
|
Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11.
|
Percent of Class Represented By Amount in Row (9)
|
12.
|
Type of Reporting Person (See Instructions)
|
CUSIP NO. 24823R105
|
|
1.
|
Names of Reporting Persons
|
2.
|
Check the Appropriate Box If a Member of a Group (See Instructions)
|
a.
|
[ ]
|
b.
|
[X]
|
3.
|
SEC Use Only
|
4.
|
Citizenship or Place of Organization
|
|
5.
|
Sole Voting Power
|
Number of
Shares
|
|
0
|
Beneficially
Owned By
Each
|
6.
|
Shared Voting Power
0
|
Reporting
Person
With
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
|
|
|
0
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
10.
|
Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11.
|
Percent of Class Represented By Amount in Row (9)
|
12.
|
Type of Reporting Person (See Instructions)
|
CUSIP NO. 24823R105
|
|
1.
|
Names of Reporting Persons
|
2.
|
Check the Appropriate Box If a Member of a Group (See Instructions)
|
a.
|
[ ]
|
b.
|
[X]
|
3.
|
SEC Use Only
|
4.
|
Citizenship or Place of Organization
|
|
5.
|
Sole Voting Power
|
Number of
Shares
|
|
0
|
Beneficially
Owned By
Each
|
6.
|
Shared Voting Power
0
|
Reporting
Person
With
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
|
|
|
0
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
|
10.
|
Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
|
11.
|
Percent of Class Represented By Amount in Row (9)
|
12.
|
Type of Reporting Person (See Instructions)
|
Item 1(a).
|
Name of Issuer:
|
|
|
|
Denali Therapeutics Inc. (the "Issuer").
|
|
|
Item 1(b).
|
Address of the Issuer's Principal Executive Offices:
|
|
|
|
161 Oyster Point Blvd.
|
|
South San Francisco, CA 94080
|
|
|
Item 2(a).
|
Name of Person Filing
|
|
|
|
This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):
|
Item 2(b).
|
Address of Principal Business Office or, if None, Residence:
|
|
|
|
The address of the principal business office of each of the Reporting Persons is 201 Main Street, Suite 1900, Fort Worth, TX 76102.
|
Item 2(c).
|
Citizenship:
|
i)
|
AKDL is a Delaware limited partnership;
|
ii)
|
Crestline SI is a Delaware limited partnership;
|
iii)
|
Crestline Management is a Delaware limited partnership;
|
iv)
|
Crestline is a Delaware corporation;
|
v)
|
Neuro Line Partners, L.P. is a Texas limited partnership;
|
vi)
|
Bratton Capital Management is a Texas limited partnership;
|
vii)
|
Bratton Capital is a Texas corporation; and
|
viii)
|
Douglas K. Bratton is a citizen of the United States.
|
Item 2(d).
|
Title of Class of Securities:
|
|
Common Stock, $0.01 par value per share (the “Common Stock”).
|
Item 2(e).
|
CUSIP Number:
|
|
|
|
24823R105
|
Item 3.
|
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
|
|
This Item 3 is not applicable.
|
|
|
Item 4.
|
Ownership:
|
|
|
Item 5.
|
Ownership of Five Percent or Less of a Class:
|
|
|
|
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following
[ ].
Neuro Line, Bratton Capital Management and Bratton Capital no longer beneficially own any securities of the Issuer.
|
|
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person:
|
|
|
|
This Item 6 is not applicable.
|
|
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
|
|
|
|
See Item 2(a)
|
|
|
Item 8.
|
Identification and Classification of Members of the Group:
|
|
|
|
This Item 8 is not applicable.
|
|
|
Item 9.
|
Notice of Dissolution of Group:
|
|
|
|
This Item 9 is not applicable.
|
|
|
Item 10.
|
Certification:
|
|
This Item 10 is not applicable.
|
Date: February 12, 2021
|
DOUGLAS K. BRATTON
|
|
|
|
By: /s/ Douglas K. Bratton
|
Date: February 12, 2021
|
CRESTLINE INVESTORS, INC.
|
|
|
|
By: /s/ Douglas K. Bratton
|
|
Douglas K. Bratton
|
|
Sole Director
|
Date: February 12, 2021
|
CRESTLINE MANAGEMENT, L.P.
|
|
|
|
By: Crestline Investors, Inc., its general partner
|
|
|
|
By: /s/ Douglas K. Bratton
|
|
Douglas K. Bratton
|
|
Sole Director
|
Date: February 12, 2021
|
CRESTLINE SI (GP), L.P.
|
|
|
|
By: Crestline Investors, Inc., its general partner
|
|
|
|
By: /s/ Douglas K. Bratton
|
|
Douglas K. Bratton
|
|
Sole Director
|
Date: February 12, 2021
|
AKDL, L.P.
|
|
|
|
By: Crestline SI (GP), L.P., its general partner
|
|
|
|
By: Crestline Investors, Inc., its general partner
|
|
|
|
By: /s/ Douglas K. Bratton
|
|
Douglas K. Bratton
|
|
Sole Director
|
Date: February 12, 2021
|
BRATTON CAPITAL, INC.
|
|
|
|
By: /s/ Douglas K. Bratton
|
|
Douglas K. Bratton
|
|
Sole Director
|
Date: February 12, 2021
|
BRATTON CAPITAL MANAGEMENT, L.P.
|
|
|
|
By: Bratton Capital, Inc., its general partner
|
|
|
|
By: /s/ Douglas K. Bratton
|
|
Douglas K. Bratton
|
|
Sole Director
|
Date: February 12, 2021
|
NEURO LINE PARTNERS, L.P.
|
|
|
|
By: Bratton Capital Management, L.P., its general partner
|
|
|
|
By: Bratton Capital, Inc., its general partner
|
|
|
|
By: /s/ Douglas K. Bratton
|
|
Douglas K. Bratton
|
|
Sole Director
|